Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Brivekimig · Ulcerative Colitis Trial sites reduced: 69 → 61 locations SanofiPhase 2 NCT06975722
  2. Minor: VS-7375 · KRAS G12D-Mutated Colorectal Cancer Trial sites expanded: 32 → 35 locations Verastem, Inc.Phase 2 NCT07659795
  3. Minor: Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA · Moderate to Severe Upper Facial Lines Trial sites expanded: 21 → 24 locations AbbViePhase 2 NCT07871513
  4. Minor: Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) Trial sites reduced: 6 → 3 locations Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 2 NCT07225959
  5. Minor: E6742 · Systemic Lupus Erythematosus Trial sites expanded: 54 → 63 locations Eisai Co., Ltd.Phase 2 NCT07515014
  6. Minor: Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis Trial sites expanded: 1 → 9 locations Eidos Therapeutics, a BridgeBio companyPhase 4 NCT07695701
  7. Minor: Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor · Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Trial sites expanded: 127 → 131 locations AbbViePhase 1/2 NCT06772623
  8. Minor: Belantamab · Multiple Myeloma When Used as Monotherapy and in Combination Treatments Trial sites expanded: 44 → 59 locations GlaxoSmithKlinePhase 1/2 NCT05714839
  9. Minor: Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and · PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) Trial sites expanded: 46 → 49 locations Relay Therapeutics, Inc.Phase 2 NCT06789913
  10. Minor: Subcutaneous Injections of Elamipretide · Barth Syndrome Trial sites expanded: 0 → 7 locations Stealth BioTherapeutics Inc.Phase 1 NCT07927972
  11. Minor: Product Surveillance Registry Trial sites expanded: 401 → 404 locations MedtronicNot specified NCT01524276
  12. Minor: Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure Trial sites expanded: 23 → 26 locations CVRx, Inc.Not applicable NCT07232030
  13. Minor: Tarlatamab · Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 Trial sites reduced: 19 → 13 locations ETOP IBCSG Partners FoundationPhase 2 NCT07203053
  14. Minor: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments · a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) Trial sites reduced: 36 → 31 locations Washington University School of MedicinePhase 2/3 NCT05269394
  15. Minor: Ocrelizumab · Primary Progressive Multiple Sclerosis Study completion pushed from Jan 19, 2028 to Apr 15, 2028 Hoffmann-La RochePhase 3 NCT04035005
  16. Minor: IPN10200 · Moderate to Severe Wrinkle-like Lines Between the Eyebrows Primary completion date changed from estimate of Dec 15, 2026 to Aug 12, 2026 IpsenPhase 3 NCT07427797
  17. Minor: Dual Study Assessing Safety and Efficacy of Buntanetap · Early AD Final enrollment: 861 participants (planned 760) Annovis Bio Inc.Phase 3 NCT06709014
  18. Minor: (Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib · Gastrointestinal Stromal Tumors Interventions modified Cogent Biosciences, Inc.Phase 3 NCT05208047
  19. Minor: LIPUS-Brain · Early Alzheimer's Disease Study completion pushed from Jul 31, 2026 to Mar 31, 2027 Sound Wave Innovation CO., LTD.Phase 3 NCT05983575
  20. Minor: IPN10200 Over Time · Moderate to Severe Wrinkle-like Lines Between the Eyebrows Primary completion date changed from estimate of Dec 15, 2026 to Sep 28, 2026 IpsenPhase 3 NCT07435428
  21. Minor: Telerehabilitation In The Home After Stroke Trial sites expanded: 27 → 32 locations University of California, Los AngelesNot applicable NCT06682429
  22. Minor: HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor Trial arms changed: 9 → 10 Jiangsu HengRui Medicine Co., Ltd.Phase 1/2 NCT07140393
  23. Minor: AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients Start date changed from estimate of Oct 2026 to Nov 1, 2026 AeroRx Therapeutics Inc.Phase 2 NCT07896252
  24. Minor: African Survey on Sepsis Knowledge (ASK) Trial sites expanded: 1 → 7 locations Claudia SpiesNot specified NCT07351344
  25. Minor: SHR-1139 in Healthy Volunteers Study completion pushed from Sep 30, 2026 to Jan 30, 2027 Atridia Pty Ltd.Phase 1 NCT07078695